MTOR and type 2 diabetes mellitus: MOVA enhances fatty acid β‐oxidation in skeletal muscle and BAT through the cAMP–PKA–p38 MAPK pathway, whereas BHIBA does so via the mTOR pathway, making both potential candidates for treating obesity, T2D and metabolic syndrome (Whitehead et al., 2021).